Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A 5th View: Discussing GBT's recent Sickle Cell Phase 3 HOPE Results for Voxelotor (Previously GBT440)

Ticker(s): GBT, Emmaus Life Sciences

Who's the expert?

Name: Dr Julie Kanter - MD

Institution: UAB

  • Associate Professor of Hematology at the University of Alabama at Birmingham and oversees the Adult Sickle Cell Clinic.  
  • Currently manages 1000 - 1100 patients with sickle cell disease.
  • Principal Investigator in a number of large clinical trials related to sickle cell disease and has been involved in the comprehensive care and research for sickle cell disease patients for the past 10 years.

Interview Questions

Please describe your background and experience with Sickle Cell Disease and any work with Voxelotor.

Added By: c_admin

What is your high level opinion of today's top-line HOPE trial data?

Added By: c_admin

On a scale of 1-10 how excited about this program are you for patients?

Added By: c_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.